Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Liabilities from Discontinued Operations (2020 - 2021)

Agios Pharmaceuticals (AGIO) has disclosed Liabilities from Discontinued Operations for 2 consecutive years, with 34533000.0 as the latest value for Q1 2021.

  • For Q1 2021, Liabilities from Discontinued Operations changed N/A year-over-year to 34533000.0; the TTM value through Mar 2021 reached 34533000.0, changed N/A, while the annual FY2020 figure was 38459000.0, N/A changed from the prior year.
  • Liabilities from Discontinued Operations hit 34533000.0 in Q1 2021 for Agios Pharmaceuticals, down from 38459000.0 in the prior quarter.
  • Across five years, Liabilities from Discontinued Operations topped out at 38459000.0 in Q4 2020 and bottomed at 34533000.0 in Q1 2021.